Welcome to our dedicated page for ERPY news (Ticker: ERPY), a resource for investors and traders seeking the latest updates and insights on ERPY stock.
ERP Technologies (ERPY) provides investors and business professionals with essential updates through this comprehensive news hub. Track official announcements including financial disclosures, product enhancements, and strategic collaborations that shape this ERP innovator's market position.
Access timely updates on earnings reports, operational milestones, and partnership developments like ERPY's collaboration with Vetophage. Our curated feed ensures you never miss critical information about software innovations or industry leadership changes.
Discover verified information about enterprise solution developments directly from primary sources. This resource serves both technical professionals seeking product details and investors monitoring organizational growth patterns.
Bookmark this page for streamlined access to ERPY's evolving business narrative. Regular updates ensure you maintain informed perspectives on this dynamic player in enterprise resource planning technology.
ERYTECH announced the top-line results of its TRYbeCA-1 Phase 3 trial evaluating eryaspase in patients with second-line advanced pancreatic cancer. The trial did not meet its primary endpoint of overall survival, reporting a median OS of 7.5 months for eryaspase plus chemotherapy vs. 6.7 months for chemotherapy alone. However, a subgroup treated with an irinotecan-based regimen showed a nominal survival benefit. ERYTECH plans to focus on its hypersensitive ALL program and intends to submit a BLA by year-end 2021.
The press release provides monthly updates on voting rights and share capital for ERYP as of September 30, 2021. As of this date, the total number of shares composing the capital is 27,923,522, with gross voting rights totaling 29,423,496 and net voting rights at 29,420,996. The data reflects a consistent increase in shares over recent months, indicating ongoing shareholder engagement and potential interest in the company. The disclosure complies with regulatory requirements set by the French financial authorities.
ERYTECH has declared the maximum tolerated dose (MTD) of its lead product candidate eryaspase at 100 U/kg in a Phase 1 trial for first-line pancreatic cancer. The trial showed no dose-limiting toxicity (DLT) in early cohorts, and the treatment demonstrated encouraging clinical activity with all patients achieving disease control. Conducted by Dr. Marcus Noel at Georgetown University, the trial is crucial for future studies. Further patient enrollment is ongoing, with top-line results expected from another trial in Q4 2021.
ERYTECH Pharma announced its participation in HealthTech Innovation Days (HTID) organized by France Biotech on October 4 & 5, 2021.
The CEO Gil Beyen and CFO Eric Soyer will engage in one-on-one investor meetings. The company focuses on developing innovative therapies via encapsulating drugs in red blood cells, with its lead product eryaspase targeting cancer metabolism. Eryaspase is in Phase 3 trials for second-line pancreatic cancer and Phase 2 trials for triple-negative breast cancer. ERYTECH is listed on NASDAQ and Euronext under ticker ERYP.
ERYTECH Pharma has filed its half-year financial report for the period ending June 30, 2021, with the AMF. The report is available on the company's website. ERYTECH is focused on developing red blood cell-based therapeutics for severe cancers and orphan diseases. Its lead candidate, eryaspase, is in Phase 3 clinical development for second-line pancreatic cancer and has received Fast Track designation from the FDA. The company operates GMP facilities in France and the U.S., but eryaspase is not yet approved.
ERYTECH has provided a business update and financial results for the first half of 2021. Key highlights include the full enrollment of the TRYbeCA-1 Phase 3 trial in second-line metastatic pancreatic cancer and expected top-line results by Q4 2021. The company aims to submit a Biologics License Application (BLA) for eryaspase in treating ALL patients with hypersensitivity to pegylated asparaginase by year-end. Financially, ERYTECH reported a net loss of €27.95 million, down 20% year-over-year, while cash and equivalents reached €44.5 million at the end of June.
ERYTECH Pharma will host its Second Quarter 2021 conference call on September 21, 2021, at 2:30 PM CEST/8:30 AM ET. The call aims to discuss operational highlights, and registration is required for participation, which can be completed via the provided link. A live webcast will also be available. ERYTECH is focused on developing innovative red blood cell-based therapies for cancer and orphan diseases using the ERYCAPS® platform. The company’s lead product, eryaspase, is in Phase 3 trials for second-line pancreatic cancer.
ERYTECH Pharma announced that its CEO, Gil Beyen, will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The event will be held virtually, and an on-demand corporate presentation will be available for attendees starting September 13 at 7am ET for 90 days. Management will also conduct one-on-one meetings with investors during the conference. ERYTECH, focused on innovative red blood cell-based therapeutics, is developing eryaspase for severe cancers and orphan diseases. The company’s lead candidate is in Phase 3 for pancreatic cancer.
The monthly update on total voting rights and shares for the company as of August 31, 2021, indicates a share capital of 27,729,047 shares. The gross voting rights total stands at 29,250,818, while net voting rights, excluding treasury shares, are at 29,248,318. This reflects an overall increase compared to previous months. The data complies with the French Autorité des Marchés Financiers regulations, ensuring transparent disclosure to shareholders and market participants.
ERYTECH Pharma announced its participation in the Citi 16th Annual BioPharma Conference from September 8-10, 2021. The company, recognized for its innovative therapies encapsulating drug substances in red blood cells, will host virtual one-on-one meetings with investors. Key executives, including CEO Gil Beyen and CFO Eric Soyer, will be present. ERYTECH is focused on its lead product candidate, eryaspase, which targets cancer metabolism and is currently in Phase 3 for second-line pancreatic cancer.
